Serum proteomic test in advanced non-squamous non-small cell lung cancer treated in first line with standard chemotherapy.

ABSTRACT:

Background

VeriStrat is a blood-based proteomic test with predictive and prognostic significance in second-line treatments for non-small cell lung cancer (NSCLC). This trial was designed to investigate the role of VeriStrat in first-line treatment of advanced NSCLC with standard chemotherapy. Here we present the results for 76 non-squamous patients treated with a combination of carboplatin or cisplatin with pemetrexed.

Methods

The test-assigned classifications of VeriStrat Good or VeriStrat Poor to samples collected at baseline. The primary end point was progression-free survival (PFS); secondary end points included overall survival (OS) and objective response. Exploratory analyses of end points separately in carboplatin/pemetrexed and cisplatin/pemetrexed subgroups were als

SUBMITTER: Grossi F 

PROVIDER: S-EPMC5220151 | biostudies-literature | 2017 Jan

REPOSITORIES: biostudies-literature